Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG with G-CSF for Stem Cell Mobilization
NCT00542529Phase 2Completed
- Sponsor
- HiberCell
- Start
- Nov 2006
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of odetiglucan in hematopoietic stem cell mobilization (2 cohorts), sponsored by HiberCell. Primary endpoint: Safety of Imprime PGG at 4 days. Started Nov 2006; status: completed.
02
Drugs
odetiglucan
03
Conditions
hematopoietic stem cell mobilization
Beyond the preview
Go deeper on NCT00542529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542529.